Summary
Johnson & Johnson announced more than 30 hematology presentations for EHA 2026, including key datasets from the Phase 3 MonumenTAL-3 and MajesTEC-9 multiple myeloma studies and pivotal Phase 2/3 ENERGY data for IMAAVY in warm autoimmune hemolytic anemia.
What Happened
J&J disclosed its EHA 2026 scientific package ahead of the June congress in Stockholm.
Key presentations include:
– Phase 3 MonumenTAL-3 results evaluating talquetamab combinations in relapsed/refractory multiple myeloma
– Encore presentation of Phase 3 MajesTEC-9 data evaluating TECVAYLI in second-line multiple myeloma
– Pivotal ENERGY study results for IMAAVY in warm autoimmune hemolytic anemia
The company emphasized continued leadership across bispecific antibodies and FcRn-targeted immune modulation.
Deep Analysis
This is a major competitive positioning signal in hematology even before the actual datasets are released.
MajesTEC-9 is one of the most important myeloma datasets of 2026 because it evaluates movement of BCMA bispecific therapy into earlier treatment lines. Strong efficacy could significantly alter treatment sequencing and pressure both CAR-T utilization and existing daratumumab-based regimens.
MonumenTAL-3 is strategically important because it expands GPRC5D bispecific combinations into pivotal-stage development.
Notably, J&J appears willing to cannibalize parts of its own Darzalex franchise to preserve long-term category leadership in myeloma.
IMAAVY also broadens the strategic importance of FcRn inhibition into hematologic autoimmunity, placing J&J into direct competition with Argenx and UCB.
Although no efficacy data have yet been presented, the prominence of these sessions strongly suggests confidence in the results.
Company / Product Background
Johnson & Johnson is a global leader in hematologic oncology and immune-mediated disease.
Talquetamab is a GPRC5D×CD3 bispecific antibody that redirects T cells against myeloma cells.
TECVAYLI (teclistamab) is a BCMA×CD3 bispecific antibody targeting multiple myeloma.
IMAAVY (nipocalimab) is an FcRn inhibitor designed to reduce pathogenic IgG autoantibodies.
Warm autoimmune hemolytic anemia is a rare autoimmune disorder characterized by antibody-mediated red blood cell destruction.
Signal Extraction
– Earlier-line bispecific therapy becoming central myeloma battleground
– J&J consolidating leadership across hematology modalities
– FcRn inhibitors expanding into hematologic autoimmune disease
– Self-cannibalization emerging as strategic defense mechanism
Insilens Take
– Opportunity: Earlier-line bispecific expansion could reshape myeloma treatment sequencing
– Threat: Intensifying competition across BCMA and GPRC5D platforms
– Watch Signal: Actual EHA efficacy and safety data
– Action: Track durability and positioning versus CAR-T
